<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[advisory committee and marketing Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/advisory+committee+and+marketing.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to advisory committee and marketing]]></description>
	<s:counts start="0" returned="3" found="3" />
	<language>en-us</language>
	<item>
		<title><![CDATA[FDA Oncologic Drugs Advisory Committee Recommends Marketing Approval for Ligand's Targretin Capsules for Treatment of Advanced-Stage Cutaneous T-Cell Lymphoma]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1999_Dec_13/ai_58183559]]></link>
		<description><![CDATA[SAN DIEGO--BW HealthWire--Dec 13, 1999--]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 13 Dec 1999 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[marketing]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[FDA Advisory Committee Recommends Clearance for Marketing of First U.S. Monoclonal Antibody for Cancer Treatment; Rituxan Reviewed for Use in Non-Hodgkin's Lymphoma]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1997_July_25/ai_19617873]]></link>
		<description><![CDATA[SAN DIEGO and SOUTH SAN FRANCISCO--BW HealthWire--July 25, 1997-- IDEC Pharmaceuticals Corporation (NASDAQ:IDPH) and Genentech, Inc.  (NYSE:GNE) today announced that RituxanTM Rituximab, also known as IDEC-C2B8, a monoclonal antibody, was recommended unanimously for marketing clearance by the Biological Response Modifiers Advisory Committee BRMAC to the U.S.  Food and...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 25 Jul 1997 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[marketing]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Eli Lilly & Company's Gemzar recommended by Advisory Committee to FDA for marketing for treatment of Advanced Pancreatic Cancer]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1995_July_24/ai_17327208]]></link>
		<description><![CDATA[ROCKVILLE, Md.--HealthWire--July 24, 1995--GemzarR gemcitabine hydrochloride, an investigational drug by Eli Lilly and Company, for the treatment of advanced or metastatic pancreatic cancer, was recommended to be cleared for marketing today by the Oncology Drug Advisory Committee ODAC of the Food and Drug Administration FDA. Gemzar is a novel nucleoside...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 24 Jul 1995 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[marketing]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
</channel>
</rss>
